Table 1 Characteristics of identified studies
Reference | Year | Inclusion period | Sample size (total/BEV) | Study type | CTX in BEV group OX/IRI/OX + IRI [%] | No BEV cycles | Interval last BEV cycle to surgery | Risk of bias |
|---|---|---|---|---|---|---|---|---|
Aussilhou | 2009 | 2002–2008 | 40/13 | Prosp. CS | 54/38 | 12 (2–36) | 92 days | High |
Constantinidou | 2013 | Until 9/2010 | 94/42 | Retrosp. CS | 64/33 | 4.5 (4–12)a | 73 (44–141) days | High |
D’Angelica | 2007 | 2004–2005 | 64/32 | Matched CCS | 56/37 | 9 (4–15) | 6.9 (3–15) weeks | High |
Kesmodel | 2008 | 2004–2006 | 125/81 | Retrosp. CS | 70/36 | 84 (14–513)b | 58 (31–117) days | High |
Klinger | 2009 | 2001–2006 | 106/56 | Retrosp. CSe | 100/0 | 5 | 5 weeks | High |
Lubezky | 2013 | 2000–2007 | 191/134 | Retrosp. CS | 72/28 | - | >6 weeks | High |
Mahfud | 2010 | 2005–2007 | 90/45 | Matched CCS | 24/71 | 9 (7–10)a | 9 weeks (60, 47–73 days) | Low |
Millet | 2012 | 2006–2011 | 82/41 | Matched CCS | 15/85 | 6 (4–16)a | 65 (39–90) days | Low |
Pessaux | 2010 | 2005–2007 | 42/21 | Matched CCS | 76/10/14 | 8.1 ± 4.7 | 11.7 ± 4.7 weeks | Low |
Reddy | 2008 | 1996–2006 | 96/39 | Retrosp. CS | 79/21 | 6 (3–8)c | 10 (8–13) weeks | High |
Ribero | 2007 | 2002–2006 | 105/62 | Retrosp. CS | 100/0 | 6 (3–12)a | >6 weeks | High |
Rong | 2014 | 2002–2012 | 501/117 | Retrosp. CS | 100/0 | 6 ± 12a | - | High |
Rubbia Brandt | 2010 | – | 274/70d | Retrosp. CS | 100/0 | - | - | High |
Tamandl | 2009 | 2005–2009 | 214/102 | Retrosp. CS | 82/13 | 6 (1–20) | 34 (17–99) days | High |
van der Pool | 2012 | 2003–2008 | 104/51 | Retrosp. CS | 100/0 | 4 (1–15)a | 11 (5–38) weeks | High |
Vera | 2014 | 2005–2011 | 95/51 | Retrosp. CS | 45/53 | 6 (1–21)a | - | High |
Wicherts | 2011 | 2005–2009 | 164/67 | Retrosp. CS | 23/68/2 | 8.6 (1–34) | 8 (3–19) weeks | Low |
Zorzi | 2008 | 1995–2007 | 43/26 | Retrosp. CS | 100/0 | 5 (3–20)a | 7.9 (3–36) weeks | High |